New hope for kids with malaria: single-dose drug may stop relapse
NCT ID NCT07052162
First seen Mar 23, 2026 · Last updated May 13, 2026 · Updated 8 times
Summary
This study tests a drug called tafenoquine in 30 children in Papua New Guinea who have vivax malaria. The goal is to see how the drug works in the body and if it can safely prevent the malaria from coming back. Children will be monitored closely for side effects and drug levels in the blood.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PHARMACOKINETICS OF TAFENOQUINE are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Alexishafen Health Centre
RECRUITINGMadang, Madang Province, MP511, Papua New Guinea
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.